Shareholders in 2seventy bio, Inc. ( NASDAQ:TSVT ) had a terrible week, as shares crashed 22% to US$3.92 in the ...

Inc. (TSVT) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $1 per share a year ago. These figures are adjusted for ...

Cash Runway: Expected to extend beyond 2027. 2seventy bio Inc (NASDAQ:TSVT) successfully completed the sale of its oncology and autoimmune R&D pipeline to Regeneron, streamlining operations. The ...

Seventy Bio, Inc. ( (TSVT) ) has released its Q3 earnings. Here is a breakdown of the information 2Seventy Bio, Inc. presented to its ...

TD Cowen analyst Yaron Werber maintained a Hold rating on 2seventy bio (TSVT – Research Report) today. The company’s shares closed ...

Good day and thank you for standing by. Welcome to the 2seventy bio Third Quarter 2024 Earnings Conference Call. At this time all participants are in a listen-only mode. After the speakers ...

2seventy bio Stock Performance NASDAQ TSVT opened at $4.73 on Friday. The stock has a market cap of $243.60 million, a price-to-earnings ratio of -1.54 and a beta of 1.78. The business has a 50 ...

On Tuesday, Goldman Sachs reiterated its Sell rating on 2Seventy Bio Inc. (NASDAQ: TSVT) with a steady price target of $2.00. The firm acknowledged that 2Seventy Bio's ...